ABCL-101 Cost-Effectiveness of Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Clinical lymphoma myeloma & leukemia/Clinical lymphoma, myeloma and leukemia（2022）
Key words
ABCL,diffuse large B-cell lymphoma,cost-effectiveness,polatuzumab vedotin
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined